financetom
Business
financetom
/
Business
/
Lufthansa weighs cancelling Frankfurt-Beijing route due to competition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lufthansa weighs cancelling Frankfurt-Beijing route due to competition
Sep 22, 2024 8:27 AM

BERLIN (Reuters) - Germany's Lufthansa is evaluating whether to cancel its daily Frankfurt-to-Beijing flights as increased competition, particularly from China, and higher costs of doing business in Europe hit its bottom line, a spokesperson said on Friday.

"Lufthansa is continuously evaluating and optimising its entire route network," said a Lufthansa spokesperson.

A final decision on whether to cut the connection from Frankfurt, Germany's busiest airport, will be made in October, said the spokesperson. Lufthansa will operate a daily flight from Munich, Germany's second-busiest airport, to Beijing.

Chinese airlines have been gaining market share on international routes as foreign airlines are deterred by weak China travel demand, rising costs and extended flight times because of the need to avoid Russian airspace.

European airlines are in unequal competition with China, as well as with airlines from the Gulf and the Bosporus, which benefit from low location costs and social standards, and high government investment in the sector, said the spokesperson.

By contrast, European airlines must deal with rising taxes and fees, high regulatory requirements and inadequate infrastructure, which hampers their international competitiveness, added the spokesperson, who called for politicians in Europe to find new industrial policy responses.

(Writing by Miranda Murray, Editing by Friederike Heine)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Reportedly Signs Licensing Deal With South Korea's Alteogen
Biogen Reportedly Signs Licensing Deal With South Korea's Alteogen
Mar 25, 2026
07:32 AM EDT, 03/25/2026 (MT Newswires) -- Biogen (BIIB) has signed a licensing deal with South Korea's Alteogen for subcutaneous biopharmaceutical formulations based on the ALT-B4 platform, a technology that converts intravenous drugs into subcutaneous injections, news outlets reported Wednesday, citing Alteogen. Under the agreement, Biogen secures exclusive rights to develop and commercialize two biopharmaceutical products using Alteogen's ALT-B4 platform...
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
Mar 25, 2026
Board to evaluate a range of alternatives while continuing to support core business priorities ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. ( NDRA ) , a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic...
I Bella Perfect Files for Nasdaq IPO to Sell 3.75 Million Shares
I Bella Perfect Files for Nasdaq IPO to Sell 3.75 Million Shares
Mar 25, 2026
07:31 AM EDT, 03/25/2026 (MT Newswires) -- I Bella Perfect (IBP) said Wednesday that it has filed to sell 3.75 million Class A shares in an initial public offering at an expected price range of $4 to $6 per share, according to an amended Form F-1 filed with the US Securities and Exchange Commission. The Malaysian aesthetic medical clinics operator...
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
Mar 25, 2026
BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ( LSBWF ) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the Special Committee) has received a revised preliminary non-binding...
Copyright 2023-2026 - www.financetom.com All Rights Reserved